MRS1523
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 532280

CAS#: 212329-37-8

Description: MRS1523 is a selective A3 adenosine receptor antagonist.


Chemical Structure

img
MRS1523
CAS# 212329-37-8

Theoretical Analysis

MedKoo Cat#: 532280
Name: MRS1523
CAS#: 212329-37-8
Chemical Formula: C23H29NO3S
Exact Mass: 399.19
Molecular Weight: 399.550
Elemental Analysis: C, 69.14; H, 7.32; N, 3.51; O, 12.01; S, 8.02

Price and Availability

Size Price Availability Quantity
5mg USD 350
10mg USD 620
25mg USD 1300
Bulk inquiry

Synonym: MRS1523; MRS 1523; MRS-1523.

IUPAC/Chemical Name: propyl 6-ethyl-5-ethylsulfanylcarbonyl-2-phenyl-4-propylpyridine-3-carboxylate

InChi Key: UUSHFEVEROROSP-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H29NO3S/c1-5-12-17-19(23(26)28-8-4)18(7-3)24-21(16-13-10-9-11-14-16)20(17)22(25)27-15-6-2/h9-11,13-14H,5-8,12,15H2,1-4H3

SMILES Code: O=C(C1=C(CCC)C(C(SCC)=O)=C(CC)N=C1C2=CC=CC=C2)OCCC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 399.55 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Di Angelantonio S, Bertollini C, Piccinin S, Rosito M, Trettel F, Pagani F, Limatola C, Ragozzino D. Basal adenosine modulates the functional properties of AMPA receptors in mouse hippocampal neurons through the activation of A1R A2AR and A3R. Front Cell Neurosci. 2015 Oct 12;9:409. doi: 10.3389/fncel.2015.00409. PubMed PMID: 26528137; PubMed Central PMCID: PMC4601258.

2: Haeusler D, Grassinger L, Fuchshuber F, Hörleinsberger WJ, Höftberger R, Leisser I, Girschele F, Shanab K, Spreitzer H, Gerdenitsch W, Hacker M, Wadsak W, Mitterhauser M. Hide and seek: a comparative autoradiographic in vitro investigation of the adenosine A3 receptor. Eur J Nucl Med Mol Imaging. 2015 May;42(6):928-39. doi: 10.1007/s00259-014-2985-2. PubMed PMID: 25739834; PubMed Central PMCID: PMC4382535.

3: Haeusler D, Kuntner C, Nics L, Savli M, Zeilinger M, Wanek T, Karagiannis P, Lanzenberger RR, Langer O, Shanab K, Spreitzer H, Wadsak W, Hacker M, Mitterhauser M. [18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents. Eur J Nucl Med Mol Imaging. 2015 Apr;42(5):741-9. doi: 10.1007/s00259-014-2976-3. PubMed PMID: 25601336; PubMed Central PMCID: PMC4349960.

4: Hedegaard ER, Nielsen BD, Mogensen S, Rembold CM, Frøbert O, Simonsen U. Mechanisms involved in increased sensitivity to adenosine A(2A) receptor activation and hypoxia-induced vasodilatation in porcine coronary arteries. Eur J Pharmacol. 2014 Jan 15;723:216-26. doi: 10.1016/j.ejphar.2013.11.029. PubMed PMID: 24309216.

5: Hinze AV, Mayer P, Harst A, von Kügelgen I. Adenosine A(3) receptor-induced proliferation of primary human coronary smooth muscle cells involving the induction of early growth response genes. J Mol Cell Cardiol. 2012 Nov;53(5):639-45. doi: 10.1016/j.yjmcc.2012.08.003. PubMed PMID: 22906537.

6: Chen Z, Janes K, Chen C, Doyle T, Bryant L, Tosh DK, Jacobson KA, Salvemini D. Controlling murine and rat chronic pain through A3 adenosine receptor activation. FASEB J. 2012 May;26(5):1855-65. doi: 10.1096/fj.11-201541. PubMed PMID: 22345405; PubMed Central PMCID: PMC3336784.

7: Chanyshev B, Shainberg A, Isak A, Litinsky A, Chepurko Y, Tosh DK, Phan K, Gao ZG, Hochhauser E, Jacobson KA. Anti-ischemic effects of multivalent dendrimeric A₃ adenosine receptor agonists in cultured cardiomyocytes and in the isolated rat heart. Pharmacol Res. 2012 Mar;65(3):338-46. doi: 10.1016/j.phrs.2011.11.013. PubMed PMID: 22154845; PubMed Central PMCID: PMC3278557.

8: Choi IY, Lee JC, Ju C, Hwang S, Cho GS, Lee HW, Choi WJ, Jeong LS, Kim WK. A3 adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats. Am J Pathol. 2011 Oct;179(4):2042-52. doi: 10.1016/j.ajpath.2011.07.006. PubMed PMID: 21854743; PubMed Central PMCID: PMC3181366.

9: Blad CC, von Frijtag Drabbe Künzel JK, de Vries H, Mulder-Krieger T, Bar-Yehuda S, Fishman P, Ijzerman AP. Putative role of the adenosine A(3) receptor in the antiproliferative action of N (6)-(2-isopentenyl)adenosine. Purinergic Signal. 2011 Dec;7(4):453-62. doi: 10.1007/s11302-011-9244-9. PubMed PMID: 21720785; PubMed Central PMCID: PMC3224645.

10: El-Awady MS, Ansari HR, Fil D, Tilley SL, Mustafa SJ. NADPH oxidase pathway is involved in aortic contraction induced by A3 adenosine receptor in mice. J Pharmacol Exp Ther. 2011 Aug;338(2):711-7. doi: 10.1124/jpet.111.180828. PubMed PMID: 21606175; PubMed Central PMCID: PMC3141902.

11: Mlejnek P, Dolezel P, Kosztyu P. P-glycoprotein mediates resistance to A3 adenosine receptor agonist 2-chloro-N6-(3-iodobenzyl)-adenosine-5'-n-methyluronamide in human leukemia cells. J Cell Physiol. 2012 Feb;227(2):676-85. doi: 10.1002/jcp.22775. PubMed PMID: 21520073.

12: Antonioli L, Fornai M, Colucci R, Ghisu N, Tuccori M, Awwad O, Bin A, Zoppellaro C, Castagliuolo I, Gaion RM, Giron MC, Blandizzi C. Control of enteric neuromuscular functions by purinergic A(3) receptors in normal rat distal colon and experimental bowel inflammation. Br J Pharmacol. 2010 Oct;161(4):856-71. doi: 10.1111/j.1476-5381.2010.00917.x. PubMed PMID: 20860664; PubMed Central PMCID: PMC2992900.

13: Piccinin S, Di Angelantonio S, Piccioni A, Volpini R, Cristalli G, Fredholm BB, Limatola C, Eusebi F, Ragozzino D. CX3CL1-induced modulation at CA1 synapses reveals multiple mechanisms of EPSC modulation involving adenosine receptor subtypes. J Neuroimmunol. 2010 Jul 27;224(1-2):85-92. doi: 10.1016/j.jneuroim.2010.05.012. PubMed PMID: 20570369.

14: Zhou R, Chen F, Li Q, Hu DY, Liu LM. Stimulation of the adenosine A3 receptor reverses vascular hyporeactivity after hemorrhagic shock in rats. Acta Pharmacol Sin. 2010 Apr;31(4):413-20. doi: 10.1038/aps.2010.18. PubMed PMID: 20348945; PubMed Central PMCID: PMC4007655.

15: Maggi L, Trettel F, Scianni M, Bertollini C, Eusebi F, Fredholm BB, Limatola C. LTP impairment by fractalkine/CX3CL1 in mouse hippocampus is mediated through the activity of adenosine receptor type 3 (A3R). J Neuroimmunol. 2009 Oct 30;215(1-2):36-42. doi: 10.1016/j.jneuroim.2009.07.016. PubMed PMID: 19709758.

16: Assaife-Lopes N, Wengert M, de Sá Pinheiro AA, Leão-Ferreira LR, Caruso-Neves C. Inhibition of renal Na+-ATPase activity by inosine is mediated by A1 receptor-induced inhibition of the cAMP signaling pathway. Arch Biochem Biophys. 2009 Sep;489(1-2):76-81. doi: 10.1016/j.abb.2009.07.003. PubMed PMID: 19709567.

17: Di Sole F, Cerull R, Babich V, Casavola V, Helmle-Roth C, Burckhardt G. Short- and long-term A3 adenosine receptor activation inhibits the Na+/H+ exchanger NHE3 activity and expression in opossum kidney cells. J Cell Physiol. 2008 Jul;216(1):221-33. doi: 10.1002/jcp.21399. PubMed PMID: 18286509.

18: Yoshikawa N, Yamada S, Takeuchi C, Kagota S, Shinozuka K, Kunitomo M, Nakamura K. Cordycepin (3'-deoxyadenosine) inhibits the growth of B16-BL6 mouse melanoma cells through the stimulation of adenosine A3 receptor followed by glycogen synthase kinase-3beta activation and cyclin D1 suppression. Naunyn Schmiedebergs Arch Pharmacol. 2008 Jun;377(4-6):591-5. PubMed PMID: 18084742.

19: Morello S, Petrella A, Festa M, Popolo A, Monaco M, Vuttariello E, Chiappetta G, Parente L, Pinto A. Cl-IB-MECA inhibits human thyroid cancer cell proliferation independently of A3 adenosine receptor activation. Cancer Biol Ther. 2008 Feb;7(2):278-84. PubMed PMID: 18059189.

20: Ansari HR, Nadeem A, Tilley SL, Mustafa SJ. Involvement of COX-1 in A3 adenosine receptor-mediated contraction through endothelium in mice aorta. Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3448-55. PubMed PMID: 17921329.